Argenx Expands VYVGART's Horizon with Key New Data in Neurology
The biopharmaceutical group argenx announces the presentation of new clinical data for VYVGART and its drug candidates at the annual American Academy of Neurology (AAN) congress taking place in Chicago from April 18 to 22, 2026. The data focus on the expansion of VYVGART's use in severe myasthenia and chronic inflammatory demyelinating polyneuropathy (CIDP), as well as progress in other muscular neurology research programs.
Argenx presents clinical data supporting the expansion of access to VYVGART beyond its currently approved indication. The company is making progress towards its goal of extending VYVGART's reach to as many patients with severe myasthenia as possible, regardless of subtype. The new data includes results from the ADAPT OCULUS study, evaluating VYVGART in subcutaneous injection for patients with ocular myasthenia, as well as results from the ADAPT SERON study on patients seronegative for anti-AChR antibodies.
Advancing Beyond VYVGART
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Beyond VYVGART, argenx is advancing multiple therapeutic programs. Data related to VYVGART Hytrulo highlight its potential to produce early clinical improvement in patients with CIDP being treated for the first time. The company is also evaluating empasiprubart in phase 3 studies for the treatment of CIDP, and presents new data for adimanebart in congenital myasthenic syndromes.
argenx continue de livrer un impact significatif pour les patients.
Argentx affiche une croissance de 63% par rapport à l'année précédente.
Risks mentioned
Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
L'impact des lois et règlements gouvernementaux pourrait affecter les activités.
Opportunities identified
VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
Lancement d'une étude pour le candidat pipeline empasiprubart.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
